AF Common, Worsens Prognosis After Stem Cell Transplant for Multiple Myeloma

Why It Matters

Post‑transplant AF signals systemic vulnerability and dramatically worsens survival, making early cardiac risk stratification essential for improving outcomes in multiple myeloma patients.

Key Takeaways

• Age >65, prior AF, obesity raise post‑transplant AF risk
• Post‑transplant AF occurs median 13 days after procedure
• AF linked to fivefold increase in overall mortality
• Non‑relapse deaths drive mortality association, not myeloma progression
• Comprehensive CV assessment before transplant recommended by cardio‑oncology guidelines

Pulse Analysis

Autologous stem cell transplantation remains a cornerstone therapy for multiple myeloma, offering deep remissions but imposing intense physiologic stress. Recent data from Memorial Sloan Kettering reveal that atrial fibrillation, the most common cardiac complication during cancer treatment, develops in roughly one in eleven transplant recipients. The retrospective cohort of 801 patients identified age above 65, a history of paroxysmal AF, and obesity as the strongest predictors, with the arrhythmia typically emerging 13 days after conditioning chemotherapy. These findings underscore the need to view AF not merely as an incidental rhythm disturbance but as a marker of heightened cardiovascular frailty.

The study’s survival analysis showed that patients who experienced post‑transplant AF faced a five‑fold increase in overall mortality and more than four‑fold rise in non‑relapse deaths, independent of myeloma progression. Editorial commentary interprets this pattern as evidence that AF reflects systemic vulnerability, often occurring alongside sepsis or respiratory failure rather than isolated cardiac triggers. Consequently, AF should be re‑classified from a procedural side effect to a prognostic indicator that flags patients with limited physiological reserve, prompting clinicians to intensify monitoring and supportive care.

Given the stark mortality signal, cardio‑oncology societies now recommend comprehensive cardiovascular assessment—including ECG and echocardiography—within six months before transplant, followed by risk‑stratified surveillance throughout the peri‑transplant period. Prospective trials are needed to determine whether early rhythm‑control strategies or preventive measures such as weight management and QT‑interval monitoring can mitigate the adverse outcomes. Until such evidence emerges, transplant teams should integrate multidisciplinary cardiac evaluation into standard protocols, ensuring that high‑risk patients receive optimized cardiovascular management alongside their oncologic therapy.